Akifumi Morinaka

Director/Board Member at Rege Nephro Co. Ltd.

Finance

Commercial Services

Health Technology

Profile

Akifumi Morinaka is currently working as an Outside Director at Rege Nephro Co. Ltd.
and as a Principal at JAFCO Group Co. Ltd.
(Private Equity) since 2019.
He previously worked as an Outside Director at Chordia Therapeutics, Inc.

Akifumi Morinaka active positions

Companies	Position	Start
JAFCO Group Co. Ltd. (Private Equity) JAFCO Group Co. Ltd. (Private Equity) Investment ManagersFinance JAFCO Group Co. Ltd. (JAFCO Group) is the private equity arm of the parent firm, JAFCO (TSE: 8595), founded in 1973. The firm is headquartered in Tokyo, Japan.	Private Equity Investor	01/11/2019
Rege Nephro Co. Ltd. Rege Nephro Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Rege Nephro Co. Ltd. is a company based in Kyoto, Japan that specializes in the research, development, production, and sales of renal disease treatment drugs. The Japanese company has developed a unique and realistic approach to induce high-efficiency differentiation from stem cells, with the aim of saving patients suffering from renal failure. The company's research and development activities focus on developing various solutions for renal disease and improving the quality of life of patients suffering from renal disease. Rege Nephro Co. was founded in 2019 by Kenji Nagafune.	Director/Board Member	-

All active positions of Akifumi Morinaka

Former positions of Akifumi Morinaka

Companies	Position	End
CHORDIA THERAPEUTICS INC.	Director/Board Member	-

See the detail of Akifumi Morinaka's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Akifumi Morinaka's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	3
JAFCO Group Co. Ltd. (Private Equity) JAFCO Group Co. Ltd. (Private Equity) Investment ManagersFinance JAFCO Group Co. Ltd. (JAFCO Group) is the private equity arm of the parent firm, JAFCO (TSE: 8595), founded in 1973. The firm is headquartered in Tokyo, Japan.	Finance
Rege Nephro Co. Ltd. Rege Nephro Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Rege Nephro Co. Ltd. is a company based in Kyoto, Japan that specializes in the research, development, production, and sales of renal disease treatment drugs. The Japanese company has developed a unique and realistic approach to induce high-efficiency differentiation from stem cells, with the aim of saving patients suffering from renal failure. The company's research and development activities focus on developing various solutions for renal disease and improving the quality of life of patients suffering from renal disease. Rege Nephro Co. was founded in 2019 by Kenji Nagafune.	Commercial Services
Chordia Therapeutics, Inc. Chordia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Chordia Therapeutics, Inc. engages in the research and development of novel therapies for cancers. It handles research and development of low-molecular-weight drugs with unprecedented new mechanisms of action in the oncology area. The company was founded by Hiroshi Miyake and Daisuke Morishita on October 12, 2017 and is headquartered in Fujisawa, Japan.	Health Technology

See company connections

Stock Market
Insiders
Akifumi Morinaka